The FDA approved the VEGF inhibitor bevacizumab-awwb for the treatment of five types of cancer: nonsquamous non-small cell lung cancer, metastatic colorectal cancer, cervical cancer, renal cell carcinoma, and glioblastoma. A biosimilar to bevacizumab, the agent is the first such drug approved for the treatment of cancer.
Cancer discovery. 2017 Oct 05 [Epub ahead of print]